Daiwa Securities Group
ALLO icon

Daiwa Securities Group’s Allogene Therapeutics ALLO Stock Holding History

Daiwa Securities Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-535
Closed -$1K – 1191
2025
Q4 		$1K Hold
535
– – ﹤0.01% 1335
2025
Q3 		$1K Hold
535
– – ﹤0.01% 1294
2025
Q2 		$1K Sell
535
-30,290
-98% -$40.2K ﹤0.01% 1242
2025
Q1 		$45K Sell
30,825
-1,106
-3% -$2.08K ﹤0.01% 1028
2024
Q4 		$68K Buy
31,931
+6,590
+26% +$16.3K ﹤0.01% 1025
2024
Q3 		$71K Sell
25,341
-1,019
-4% -$2.72K ﹤0.01% 1034
2024
Q2 		$61K Sell
26,360
-4,178
-14% -$12.3K ﹤0.01% 1078
2024
Q1 		$137K Sell
30,538
-1,960
-6% -$8.18K ﹤0.01% 1028
2023
Q4 		$104K Buy
32,498
+17,471
+116% +$49.6K ﹤0.01% 1009
2023
Q3 		$48K Hold
15,027
– – ﹤0.01% 1062
2023
Q2 		$75K Buy
15,027
+14,492
+2,709% +$78.4K ﹤0.01% 1048
2023
Q1 		$3K Hold
535
– – ﹤0.01% 1174
2022
Q4 		$3K Hold
535
– – ﹤0.01% 1184
2022
Q3 		$6K Hold
535
– – ﹤0.01% 1152
2022
Q2 		$6K Buy
535
+119
+29% +$1.06K ﹤0.01% 1156
2022
Q1 		$4K Hold
416
– – ﹤0.01% 1185
2021
Q4 		$6K Sell
416
-71
-15% -$1.25K ﹤0.01% 1179
2021
Q3 		$13K Buy
487
+208
+75% +$4.94K ﹤0.01% 1120
2021
Q2 		$7K Hold
279
– – ﹤0.01% 1058
2021
Q1 		$10K Buy
279
+15
+6% +$506 ﹤0.01% 1045
2020
Q4 		$7K Sell
264
-523
-66% -$17K ﹤0.01% 1033
2020
Q3 		$30K Buy
787
+99
+14% +$3.73K ﹤0.01% 964
2020
Q2 		$13K Hold
688
– – ﹤0.01% 1050
2020
Q1 		$13K Hold
688
– – ﹤0.01% 1038
2019
Q4 		$18K Buy
+688
New +$18.9K ﹤0.01% 1020

Other funds holding ALLO

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Daiwa Securities Group's ALLO Position: Q1 2026 in Review

Daiwa Securities Group sold out of Allogene Therapeutics (ALLO) in Q1 2026, closing a stake of 535 shares — an estimated $1K sold.

Daiwa Securities Group first reported a position in ALLO in Q4 2019 and held it in 25 quarters. The position peaked at $137K in Q1 2024. 209 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Daiwa Securities Group reported no remaining Allogene Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 535 Allogene Therapeutics shares in Q1 2026, an estimated $1K.
  • Daiwa Securities Group first reported a position in Allogene Therapeutics in Q4 2019 and held it in 25 quarters.
  • Daiwa Securities Group's Allogene Therapeutics position peaked at $137K in Q1 2024.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.